A Novel Approach to Migraine -
A Challenge Faced by Millions
At Kallyope, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine. Our late-stage pipeline focuses on delivering an effective, easy to use, first-in-class medication.
Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers.
Our Team
Our accomplished team brings together agile innovation and real-world focus to create major value for patients.
Our Pipeline
Elismetrep, our lead asset being developed for the acute treatment of migraine, is in Phase 3.
Our Culture
Out to do things differently
This is our guiding mission: to deliver cutting-edge solutions to the world’s most challenging diseases. We are:
